Insights › Likitanci da magunguna › November 14, 2026
Likitanci da magunguna · Ayyukan da ake kan yi da ci gaba

CagriSema wanda kamfanin Novo ke bincike, wani nau'in maganin GLP-1 da amylin analog, ya nuna kimanin kashi 21% na asarar nauyi a matsakaita tare da ƙananan allurai a cikin gwajin REDEFINE 9, wanda aka gabatar a ObesityWeek® 2026 kuma aka buga a The Lancet Diabetes & Endocrino

PR Newswire (Health) An wallafa: Pipeline

Gwajin REDEFINE 9 ya nuna cewa CagriSema 1.7 mg / 1.7 mg da 1.0 mg / 1.0 mg sun samar da kiyasin matsakiyar asarar nauyi na 20.7% da 21.0%, bi da bi, a makonni 68, idan aka kwatanta da 2.0% tare da placebo, a cikin manya masu kiba ko wuce kima, idan duk marasa lafiya sun ci gaba da magani1 REDEFINE 9 ita ce ta farko...

Asalin tushe
Karanta tushen — prnewswire.com ↗

Muna haɗawa da ainihin mai wallafawa. Taƙaitawar da ke sama jagora ce kawai; karanta asalin don cikakken bayani.

Ƙari a Likitanci da magunguna

Duba komai a cikin Likitanci da magunguna →

Ƙara bincika wannan batu

Karanta kowane bayani da yarenka

Wannan shafi yana nuna sabbin abubuwa uku ne kawai a kowane fanni. Mambobi na ganin kowane bayani a cikin fannin, a harsuna 109, tare da injinan bincike da ke aiki a kansu.

Karanta duka — fara daga $3Babu buƙatar shigarwa daga kantin manhajoji. Ana iya soke shi kowane lokaci.